Race-based therapeutics

Current Hypertension Reports

Volumn 10, Issue 4, 2008, Pages 276-285

  Yancy, Clyde W ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; METHACHOLINE; METOPROLOL; N(G) METHYLARGININE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PLACEBO; PRAZOSIN; RAMIPRIL; THIAZIDE DIURETIC AGENT; VALSARTAN; VASODILATOR AGENT;

ADJUVANT THERAPY; AFRICAN AMERICAN; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; DRUG WITHDRAWAL; ETHNICITY; GENETIC VARIABILITY; GENOTYPE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HOMEOSTASIS; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MONOTHERAPY; PATIENT COMPLIANCE; PHARMACOGENOMICS; PHENOTYPE; PRACTICE GUIDELINE; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; PHARMACOGENETICS; RACE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; CONTINENTAL POPULATION GROUPS; HEART FAILURE; HOMEOSTASIS; HUMANS; HYPERTENSION; NITRIC OXIDE; PHARMACOGENETICS; PRACTICE GUIDELINES AS TOPIC; VASODILATOR AGENTS;

EID: 52449105489     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-008-0052-8     Document Type: Review

References (53)

1. Williams DR, Rucker TD: Understanding and addressing racial disparities in health care. Health Care Financ Review 2000, 21:75-90.
2. American Heart Association. 2003 Heart Disease and Stroke Statistics-Update. Dallas TX: American Heart Association; 2002.
3. American Heart Association. Heart Disease and Stroke Statistics - 2008 Update. Dallas, TX: American Heart Association; 2008.
4. Yancy CW: Heart failure in African Americans: a cardiovascular engima. J Card Fail 2000, 6:183-186.
5. Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
6. Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003, 290:199-206.
7. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997, 157:2413-2446.
8. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998, 317:703-713.
9. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
10. Wright JT, Bakris G, Greene T. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 2002, 288:2421-2431.
11. Prisant LM, Neutel JM, Ferdinand K, et al.: Low-dose combination therapy as first-line hypertension treatment for blacks and nonblacks. J Natl Med Assoc 1999, 91:40-48.
12. Douglas JG, Bakris GL, Epstein M, et al.: Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003, 163:525-541.
13. Hunt SA, Abraham WT, Chin MH, et al.: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154-e235.
14. Dries DL, Exner DV, Gersh BJ, et al.: Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999, 340:609-616.
15. Yancy CW: Heart failure in African Americans. Am J Cardiol 2005, 96(7B):3i-12i.
16. Taylor AL, Ziesche S, Yancy C, et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049-2057.
17. Exner DV, Dries DL, Domanski MJ, et al.: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001, 344:1351-1357.
18. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
19. Cohn JN, Tognoni G, Glazer R, Spoprmann D: Baseline demographics of the Valsartan Heart Failure Trial. ValHeFT Investigators. Eur J Heart Fail 2000, 345:1667-1675.
20. Pfeffer MA, Swedberg K, Granger CB, et al.; CHARM Investigators and Committees: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM Overall Programme. Lancet 2003, 362:759-766.
21. Julius S, Weber M, Kjeldsen S, et al.: The Valsartan Antihypertension Long Term Use Evaluation [VALUE] Trial: outcomes in patients receiving monotherapy. Hypertension 2006, 48:385-391.
22. Shekelle PG, Rich MW, Morton SC, et al.: Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003, 41:1529-1538.
23. The Beta-Blocker Evaluation of Survival Trial Investigators: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001, 344:1659-1667.
24. Andreka P, Aiyar N, Olson LC, et al.: Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 2002, 105:2429-2434.
25. Yancy CW, Fowler MB, Colucci WS, et al.: Race and the response to adrenergic blockade with carvedilol in patients with heart failure. N Engl J Med 2001, 344:1358-1365.
26. Carson P, Fowler MB, Mohacsi P, et al.: Effect of carvedilol in black patients with severe chronic heart failure: results of the COPERNICUS Study [abstract]. Circulation 2001, 104(Suppl II):II-754.
27. Effect of metoprolol CR/XL in chronic heartfailure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
28. Zheng ZJ, Croft JB, Giles WH, Mensah GA: Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001, 104:2158-2163.
29. Hjalmarson A: Prevention of sudden cardiac death with beta blockers. Clin Cardiol 1999, 22(Suppl 5):V11-V15.
30. McMurray J, Kober L, Robertson M, et al.: Antiarrhythmic effect of carvedilol after acute myocardial infarction Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005, 45:525-530.
31. Abraham WT, Massie BM, Franciosa JA, et al.: Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: Insights from a large prospective beta-blocker registry. Presented at the Heart Failure Society of America 7th Annual Scientific Meeting; September 22, 2003; Las Vegas, NV [abstract 348]. J Card Fail 2003, 9(Suppl 1):S94.
32. Cohn JN, Archibald MP, Ziesche S, et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986, 314:1547-1552
33. Pierpont GL, Cohn JN, Franciosa JA, et al.: Combined oral hydralazine-nitrate therapy in left ventricular failure: hemodynamic equivalency to sodium nitroprusside. Chest 1978, 73:8-13
34. Cohn JN, Johnson G, Ziesche S, et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303-310.
35. Carson P, Ziesche S, Johnson G, et al.: Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 1999; 5:178-187.
36. Yancy CW, Ghali JK, Braman VM, et al.: Results of the extension to A-HeFT [X-A-HeFT] support the continued safety and tolerability of fixed dose isosorbide dinitrate/ hydralazine. J Card Fail 2006, 12:S80.
37. Kahn DF, Duffy SJ: Effects of black race on forearm resistance vessel function. Hypertension 2002, 40:195-201.
38. Cardillo C, Kilcoyne CM, Cannon RO, et al.: Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension 1998, 31:1235-1239.
39. Kalinowski L, Dobrucki, IT, Tomasian D, et al.: Race-specific differences in endothelial function: predisposition of African Americans to vascular disease. Circulation 2004, 109:2511-2517.
40. Prabhu SD: Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart. Circ Res 2004, 94:115-157.
41. Hare JM: Nitroso-redox balance in the cardiovascular system. N Engl J Med 2004, 351:2112-2114.
42. Malinski T: Understanding nitric oxide physiology in the heart: a nanomedical approach. Am J Cardiol 2005, 96(Suppl):13i-24i.
43. Wollert KC, Drexler H: Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis. Heart Fail Rev 2002, 7:317-325.
44. Janssens S, Pokreisz P, Schoonjans L, et al.: Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 2004, 94:1256-1262.
45. McNamara DM, Tam SW, Sabolinski ML, et al.: Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial. J Am Coll Cardiol 2007, 48:1277-1282.
46. Peterson ED, Shaw LK, DeLong ER, et al.: Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter? N Engl J Med 1997, 336:480-486.
47. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E: C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension. 2001, 37:739-743.
48. Suthanthiran M, Li B, Song JO, et al.: Transforming growth factor-betal hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci 2000, 97:3479-3484.
49. Mason DA, Moore JD, Green SA, Liggett SB: A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem. 1999, 274:12670-12674.
50. Small KM, Wagoner LE, Levin AM, et al.: Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002, 347:1135-1142.
51. McNamara D: Pharmacogenetics in heart failure: genomic markers of endothelial and neurohumoral function. Congest Heart Fail 2004, 10:302-308.
52. McNamara DM, Holubkov R, Postava L, et al.: Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 2004, 44:2019-2026.
53. McNamara DM, Holubkov R, Postava L, et al.: Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure. Circulation 2003, 107:1598-1602.